Search clinical trials for: Remdesivir (RDV)

Total 1236 results

Gilead Sciences

Completed

Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation

COVID-19

United States
Gilead Sciences

Terminated

Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting

COVID-19

United States, Spain, Denmark, United Kingdom
Gilead Sciences

Terminated

Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19) (REDPINE)

COVID-19

Spain, United States, United Kingdom, Portugal, Brazil, South Africa
Daewoong Pharmaceutical Co. LTD.

Terminated

Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients

Severe COVID-19

Korea, Republic of
Tibotec Pharmaceuticals, Ireland

Completed

TMC114-TiDP3-C182 - A Study to Compare the Oral Bioavailability of a 800 mg Prototype Tablet Formulation of Darunivar (DRV) to That of the 400 mg Commercial Tablet Formulation in the Presence of Low Dose Ritonavir, Under Fasted and Fed Conditions

HIV Infections
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis

Hepatitis C Virus Infection

United States
Capital Medical University
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Suspended

A Trial of Remdesivir in Adults With Mild and Moderate COVID-19

COVID-19 | SARS-CoV-2

China
University of Pecs
Hungarian Ministry of Innovation and Technology; HECRIN Consortium

Unknown

REMdesivir-HU Clinical Study and Severe Covid-19 Patients

SARS-CoV-2 Infection

Hungary
Pfizer

Completed

A Study Comparing The Effects Of Epoetin Hospira Single-Dose Vial (SDV) And Multi-Dose Vial (MDV) When Administered Subcutaneously To Normal Healthy Subjects

Healthy

United States
Capital Medical University

Terminated

A Trial of Remdesivir in Adults With Severe COVID-19

COVID-19 | SARS-CoV-2 | Remdesivir

China
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection

HCV Infection

France
Lisa Barrett
Nova Scotia Health Authority; Dalhousie University

Active, not recruiting

Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients

COVID-19

Canada
Copycat Sciences LLC

Completed

First-in-Human Study of Orally Administered GS-441524 for COVID-19

COVID-19

United States
National Institute of Allergy and Infectious Diseases...
PPD; University of Washington; Vanderbilt University Medical Center; Implicit Bioscience

Terminated

COVID-19 and Anti-CD14 Treatment Trial (CaTT)

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | Coronavirus Disease 2019 (COVID-19)

United States
Lebanese University
Hospital Saydet Zgharta University Medical Center

Recruiting

LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients (LUSZ_AVIST)

COVID-19 | Hospitalized COVID-19 Patients

Lebanon
Gilead Sciences

Completed

Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3

Chronic Hepatitis C Infection

New Zealand
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir/Ledipasvir ± Ribavirin in Japanese Participants With Chronic Genotype 1 HCV Infection

Chronic HCV Infection

Japan
Tehran University of Medical Sciences
Bakhtar Bioshimi Co

Completed

Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1 (SL50)

Hepatitis C | Cirrhosis

Iran, Islamic Republic of
Gilead Sciences

Completed

Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects

Chronic Hepatitis C Virus

United States
NEAT ID Foundation
Gilead Sciences

Recruiting

Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir. (909REM)

Covid19

Spain, Israel, France, United Kingdom, Netherlands
Semmelweis University

Completed

Safety of Remdesivir Treatment in COVID-19 Patients Requiring Hemodialysis (REM-HD)

Covid19 | End Stage Renal Failure on Dialysis

Hungary
Gilead Sciences

Completed

Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency

HCV Infection

New Zealand, United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...
Gilead Sciences

Completed

PK and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the US

COVID-19

United States
Assistance Publique - Hôpitaux de Paris

Completed

Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections (REMDECO-19)

COVID-19

France
Mansoura University

Unknown

Remdesivir in Adults With Covid-19: Mansoura University Hospital Experience

Pneumonia, Viral

Egypt
University Hospital, Toulouse

Withdrawn

Rehabilitation Exercise With MObile Technology and Education After Acute Coronary Syndrome (REMOTE-ACS)

Acute Coronary Syndrome

France
Makerere University
University of Turin, Italy; University of Liverpool; European and Developing...

Completed

Drug-drug Interactions Between Remdesivir and Commonly Used Antiretroviral Therapy (RemTLAR)

HIV/AIDS | Ebola

Uganda
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant

Chronic HCV Infection

Belgium, Austria, New Zealand, United Kingdom, Germany, Spain, Netherlands, France, Switzerland, Canada, Australia, Italy
Gilead Sciences

Terminated

Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies

Hepatitis C Virus Infection

United States, Canada, Puerto Rico
Clinical Urology and Epidemiology Working Group
Helsinki University Central Hospital; Oulu University Hospital; Kuopio University... and other collaborators

Recruiting

SOLIDARITY Finland Long-COVID (Remdesivir Long-term Follow-up Study of COVID Patients)

Covid19

Finland
Lahore General Hospital

Unknown

Remdesivir in COVID-19 Lahore General Hospital (RC19LGH)

SARS-CoV Infection

Pakistan
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection

Chronic HCV Infection

United States
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant

Chronic HCV Infection

United States
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection

Hepatitis C Virus Infection

Egypt
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection

Hepatitis C Virus Infection

Canada
Gilead Sciences

Completed

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders

Chronic HCV Infection

United States
Gilead Sciences

Completed

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection

HIV | Hepatitis C Virus

United States, New Zealand, Canada, Puerto Rico
Universidad Nacional de Colombia

Completed

Introduction Study of Dual HIV & Syphilis Rapid Diagnostic Tests in Antenatal Clinics in Colombia

HIV | Syphilis

Colombia
University of Derby
University of Exeter; University Hospitals of Derby and Burton NHS Foundation... and other collaborators

Not yet recruiting

An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID. (ERASE-LC)

COVID-19 | SARS-CoV-2 Infection

United Kingdom
Astana Medical University

Completed

Antiviral Drugs on the Treatment of SARS-CoV-2 (FavRem)

Pneumonia, Viral | Complication of Medical Care

Kazakhstan
National Institute of Allergy and Infectious Diseases...

Completed

Adaptive COVID-19 Treatment Trial (ACTT)

COVID-19

United States, Denmark, Japan, Mexico, Spain, Korea, Republic of, Germany, Greece, Singapore, United Kingdom
Bernadette Dian Novita, MD.,PhD

Completed

OBSERVATIONAL STUDY OF COMPARISON EFFECTIVITY BETWEEN REMDESIVIR AND FAVIPIRAVIR IN SURABAYA, INDONESIA

Duration of Hospitalization | Clinical Manifestation of COVID-19

Indonesia
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection (ION-2)

Chronic Hepatitis C Virus

United States
The University of Texas Health Science Center,...

Completed

Effects of Animal Assisted Activity on Biobehavioral Stress Responses of Hospitalized Children: A Randomized Control Trial

Psychosocial Stress

United States
Professor Dr. Bernd Mühlbauer
Dept. of Statistics and Medical Biometry, University of Bremen; INSERM (Institut... and other collaborators

Unknown

An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY

COVID-19 | SARS-CoV-2 Infection | Moderate and Severe COVID-19

Germany
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)

Chronic Hepatitis C Virus

United States
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection

Hepatitis C Virus Infection

Japan
MedImmune LLC

Completed

A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults

Respiratory Syncytial Virus (RSV)

United States
National Institute of Allergy and Infectious Diseases...

Completed

ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19

COVID-19

United States
National Institute of Allergy and Infectious Diseases...
Gilead Sciences

Completed

GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen

Ebola

Guinea, Liberia

3

Subscribe